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AbstrACt
Objectives To determine the frequency of missed 
opportunities (MOs) among patients newly diagnosed with 
HIV, risk factors for presenting MOs and the association 
between MOs and late presentation (LP) to care.
Design Retrospective analysis.
setting HIV outpatient clinic at a Swiss tertiary hospital.
Participants Patients aged ≥18 years newly presenting 
for HIV care between 2010 and 2015.
Measures Number of medical visits, up to 5 years 
preceding HIV diagnosis, at which HIV testing had 
been indicated, according to Swiss HIV testing 
recommendations. A visit at which testing was indicated 
but not performed was considered an MO for HIV testing.
results Complete records were available for all 201 
new patients of whom 51% were male and 33% from 
sub-Saharan Africa. Thirty patients (15%) presented with 
acute HIV infection while 119 patients (59%) were LPs 
(CD4 counts <350 cells/mm3 at diagnosis). Ninety-four 
patients (47%) had presented at least one MO, of whom 44 
(47%) had multiple MOs. MOs were more frequent among 
individuals from sub-Saharan Africa, men who have sex 
with men and patients under follow-up for chronic disease. 
MOs were less frequent in LPs than non-LPs (42.5% vs 
57.5%, p=0.03).
Conclusions At our centre, 47% of patients presented 
at least one MO. While our LP rate was higher than the 
national figure of 49.8%, LPs were less likely to experience 
MOs, suggesting that these patients were diagnosed late 
through presenting late, rather than through being failed 
by our hospital. We conclude that, in addition to optimising 
provider-initiated testing, access to testing must be 
improved among patients who are unaware that they are 
at HIV risk and who do not seek healthcare.
IntrODuCtIOn 
Late presentation (LP) to care among 
people living with HIV prolongs the period 
between seroconversion and treatment, and 
leads to an avoidable increase in morbidity, 
mortality, healthcare costs and risk of onward 
transmission.1 In Europe, even in countries 
with adequate healthcare provision and HIV 
testing recommendations, LPs make up to 
half of all new HIV diagnoses.2 In Switzerland, 
while 81% of adults living with HIV in 2012 
were estimated to be diagnosed,3 49.8% of 
patients diagnosed and enrolled in the Swiss 
HIV Cohort Study between 2009 and 2012 
were LPs, with CD4 counts below 350 cells/
mm3 and/or an AIDS-defining illness at 
presentation.4
To maximise early HIV diagnosis, HIV 
testing recommendations have been 
published by the Swiss Federal Office of 
Public Health since 2007 and updated three 
times.5–8 In 2007, the recommendations 
introduced physician-initiated counselling 
and testing (PICT), proposing targeted 
testing and describing HIV testing indica-
tions in the text.5 In 2010, testing indications 
were mentioned in the text and presented 
as tables.6 Although the term HIV-associ-
ated indicator conditions (HIV ICs) was not 
in general use at this time, HIV ICs were 
included in the 2010 recommendations. In 
2013, the recommendations highlighted HIV 
ICs and introduced HIV screening of patients 
commencing immunosuppressive therapy.7 It 
strengths and limitations of this study
 ► We defined the term, ‘missed opportunities’, cur-
rently lacking a consensus definition, based on the 
Swiss HIV testing recommendations applicable to 
our institution.
 ► A centralised database enabled us to examine all 
patient episodes at our centre, to determine the 
number and type of missed opportunities.
 ► We used multivariate logistic regression to show a 
robust association between patient characteristics 
and the risk of missed opportunities for HIV testing.
 ► As with any monocentric study, our findings may not 
be applicable to all centres in Switzerland, due to 
differences in hospital structure and local patient 
population.
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also became medically indefensible to not propose HIV 
testing to a patient presenting testing indications. In 2015, 
the content of the recommendations remained similar, 
but the table of symptoms and signs of acute HIV infec-
tion was presented first to emphasise this clinical presen-
tation as an indication for HIV testing.8 In summary, apart 
from the addition of screening of patients commencing 
immunosuppressive therapy in 2013, the recommenda-
tion updates between 2010 and 2015 involved changes in 
format but not overall content.
The Swiss healthcare system is based on compulsory 
individual health insurance coverage, which is regu-
lated at a federal level. It is estimated that >98% of the 
population has coverage, and access to care is excel-
lent.9 For vulnerable populations, including undoc-
umented migrants, healthcare is provided through 
cantonal social services which cover health insurance 
charges, although not all individuals may be aware of 
this. We have observed that some vulnerable popula-
tions, for example, sex workers, use the emergency 
department (ED) as a primary healthcare facility10 
and that fewer than 90% of patients presenting to the 
ED have a primary care physician.11 Further, Switzer-
land has among the highest out-of-pocket costs in the 
Organisation for Economic Co-operation and Devel-
opment.9 While HIV testing is covered under basic 
health insurance, costs can be attributed directly to 
the patient according to their specific health insur-
ance package or if testing is performed on the demand 
of the patient, rather than on the recommendation of 
a physician.
When an individual presents to a healthcare provider 
with indications for HIV testing but is not offered a 
test, this constitutes a missed opportunity (MO) for 
HIV testing, regardless of his/her serostatus.1 In 2016, 
several studies were published on MOs in Europe12–15 
and Israel16 (online supplementary table S1). These 
studies covered a period of 4–7 years between 2007 and 
2015 and reported MO rates of 14.5%–34%.15 13 Many 
highlighted the importance of physician awareness of 
testing indications in reducing MOs.12 15 16 While the 
Swiss PICT recommendations, by definition, empha-
sise the responsibility of the physician in proposing 
HIV testing, we have observed that, for example, only 
18% of ED doctors in French-speaking Switzerland were 
aware of the 2010 Swiss Federal Office of Public Health 
recommendations and that, even if aware, they did not 
adhere to them.17 In the ED and other services at our 
centre, these recommendations made no difference to 
HIV testing rates.18
The aims of this study were therefore to determine 
the frequency of MOs among newly diagnosed patients 
presenting for care at our outpatient HIV service, and 
patient risk factors for presenting MOs, and to determine 
the association between MOs and LP to care.
MethODs
Due to the retrospective design, the requirement of 
patient informed consent was waived.
Patient and public involvement statement
The study being retrospective, patients or the public were 
not involved in the design or in the conduct of the study.
study setting
The study was conducted at Lausanne University 
Hospital, a 1500-bed teaching hospital which serves 
as a primary-level community hospital for Lausanne 
(catchment population 300 000) and as a secondary 
and tertiary referral hospital for Western Switzerland 
(catchment population 1–1.5 million). HIV seropreva-
lence in the region is estimated to be 0.2%–0.5%.3 19 At 
Lausanne University Hospital, medical records are elec-
tronic and include all hospital visits, discharge summaries 
(inpatients), clinical letters (outpatients) and laboratory 
reports.
In Switzerland, health insurance is mandatory. While 
most patients have a primary care physician, individuals 
may visit a specialist without referral. Outpatient HIV 
care at Lausanne University Hospital is provided by the 
infectious diseases service. All patients are invited to 
be enrolled in the Swiss HIV Cohort Study, a national 
prospective cohort study with ongoing enrolment since 
1988.20
Definitions
LP was defined as presenting for care with chronic HIV 
infection with a CD4 count <350 cells/mm3, in accordance 
with the European consensus working group definition.21
Acute HIV infection was defined as a positive blood 
HIV-RNA assay or a positive p24 antigen assay with an 
incomplete Western blot.22
The term MO for HIV testing has no consensus defini-
tion. For this study, a MO was defined as a visit to Lausanne 
University Hospital at which HIV testing was indicated 
but not performed, regardless of the serostatus of the 
patient. Testing was considered as indicated according to 
five broad indications, based on the Swiss Federal Office 
of Public Health 2015 recommendations8 but present 
in the recommendations from 2010 onwards: signs and 
symptoms of acute HIV infection; AIDS-defining illness; 
HIV ICs8 (such as herpes zoster, ongoing mononucleo-
sis-like illness or unexplained thrombocytopenia)23 24; 
situations in which HIV infection should be excluded (eg, 
planned immunosuppressive treatment and pregnancy) 
and epidemiological risk (belonging to or having a sexual 
partner from a high-risk group: men who have sex with 
men (MSM), people who inject drugs (PWIDs) and 
individuals originating from a high-prevalence region, 
notably, sub-Saharan Africa).8
Since 2013, when it became a legal responsibility for 
the physician to propose HIV testing when indicated,7 
any test offered but refused by the patient has been docu-
mented in the medical notes. The situation in which HIV 
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testing was documented as indicated and proposed, but 
declined by the patient, was therefore not considered as 
a MO.
study design
The study retrospectively analysed all patients with 
newly diagnosed HIV presenting to the Lausanne Univer-
sity Hospital infectious diseases outpatient clinic from 1 
January 2010 to 31 December 2015.
For each patient, the following data were collected: 
sociodemographic data (age, sex, geographical origin, 
marital status, risk factor(s) for HIV acquisition); HIV 
infection data (CD4 count, AIDS-defining illness, mode of 
infection); visits to Lausanne University Hospital during 
the 5 years preceding HIV diagnosis (chronic disease 
with regular follow-up, inpatient and outpatient consul-
tations) and HIV testing data (date of previous negative 
HIV test as referred to in clinic letters or obtained from 
the laboratory database, reason for performing diag-
nostic test, site of diagnostic test). The limit of 5 years for 
Lausanne University Hospital visits was selected based on 
the LP figure of 49.8% of patients newly enrolled in the 
Swiss HIV Cohort Study,4 in whom infection was likely to 
have occurred within 5 years preceding diagnosis,25 and 
the observation that, elsewhere in Europe, 59% of new 
patients with HIV exhibited HIV ICs during a similar 
prediagnosis period.26 MOs were identified using medical 
records and analysed by absolute MO number and by MO 
category (based on the five groups of HIV testing indica-
tions: acute HIV, AIDS-defining illness, HIV ICs, test of 
exclusion and epidemiological risk).
Given the low HIV testing rates observed in the ED 
at our centre and elsewhere in French-speaking Swit-
zerland (1% of all patients seen),17 18 we additionally 
conducted a search of all prediagnosis visits to the ED, 
using the central hospital database. We focused on ED 
visits estimated to have occurred after HIV seroconver-
sion based on CD4 cell count at diagnosis, accounting 
for variations related to age and sex.25 All prediagnosis 
visits were matched with laboratory reports to determine 
whether HIV testing had been performed. A single predi-
agnosis ED visit after which testing was performed within 
72 hours was not considered a MO, to allow for patients 
admitted prior to the weekend or referred for testing by 
a designated hospital team, where testing may be delayed 
in the interest of continuity of care. At the time of this 
study, rapid HIV testing was not available in the ED and so 
all HIV tests requested and performed were documented 
in the laboratory database.
Data and statistical analysis
Patient details, stripped of all identifiers, were entered 
into a coded database by the study investigators (LL, 
EM) for each of the six 12-month periods. Categorical 
data were presented as absolute frequencies and percent-
ages and compared using the χ2 test; continuous data 
were presented as means (SD) or medians (IQR) and 
analysed using the Mann-Whitney U test. Multivariate 
logistic regression was applied to calculate the adjusted 
OR for various risk factors for presenting MOs. Data 
were stratified according to patient demographic, clinical 
and epidemiological characteristics in order to reduce 
confounding. Patients with acute HIV infections were 
excluded from all analyses concerning LP.
All analyses were performed using Stata V.14.1 
(StataCorp).
results
Patient characteristics
We identified 201 patients newly presenting for HIV care 
during the study period, all of whom had complete elec-
tronic medical records. Mean age at diagnosis was 38 
years±SD (range 18–75 years). Mode of HIV transmission 
was listed as heterosexual in 57% of patients, MSM in 
34%, PWID in 4% and unknown in 5% (table 1). The 
majority of patients (59%) had never been HIV tested 
prior to their diagnostic test.
Missed opportunities
In total, 359 separate MOs were presented by 94 patients 
(47%) during the 5 years preceding their diagnosis 
(figure 1). Considering patients presenting MOs, 74 
patients (78%) had presented on more than one visit 
(range 2–17) with a MO of any category. Considering 
MO categories, 58 patients (62%) had presented a single 
category of MO, 30 patients had presented two categories 
(32%) and 6 patients (6%) had presented three catego-
ries. Figure 2 shows the distribution of MO categories by 
testing indication.
risk factors for MOs
In multivariate analysis, older patients (aged >50 years) 
had less risk of presenting MOs than patients aged <30 
years (p=0.01), while patients of sub-Saharan African 
origin (p=0.01), those under regular follow-up for chronic 
illness (p=0.01) and MSM (p=0.02) had increased risk 
(table 1). In patients from sub-Saharan Africa and those 
under regular follow-up for chronic illness, all MO cate-
gories were distributed equally compared with the rest of 
the population. In contrast, MOs in MSM patients were 
more frequently related to epidemiological risk (46%) 
than to other MO categories (33%) (p<0.01).
Clinical presentation at diagnosis, site of testing and reason 
for testing
Most patients (85%) were diagnosed in the chronic phase 
of infection (table 2). The median CD4 count at diagnosis 
was 293 (IQR 147–452). In total, 119 (59%) were LPs. LPs 
consulted less often to Lausanne University Hospital than 
non-LPs (mean number of consults 1.4 for LPs vs 2.5 for 
non-LPs, p<0.01).
A greater proportion of new HIV diagnoses were made 
in the primary care and outpatient settings than during 
hospital admission (table 2). The top three reasons for 
testing, regardless of testing site, were presence of HIV 
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ICs, epidemiological risk and symptoms and signs of acute 
HIV infection (online supplementary table S2). Acute 
HIV infection was confirmed in 24 of the 36 patients 
presenting with symptoms and signs of acute HIV infec-
tion (online supplementary table S3).
We did not identify any situations in which HIV testing 
was proposed but declined by the patient.
MOs and lP
Multivariate analysis demonstrated a lower risk of LP 
in patients presenting MOs (OR 0.5, 95% CI 0.2 to 0.9, 
p<0.01). Indeed, the median CD4 count at diagnosis 
among MO patients was significantly higher than for 
non-MO patients (351 cells/mm3 vs 244 cells/mm3, 
p<0.01). MOs were less frequent in LPs compared with 
patients presenting with CD4 >350 cells/mm3 (42.5% vs 
57.5%, p<0.01). Among subgroups, the LP rate among 
MSM was lower compared with the rest of the study popu-
lation (22% vs 78%, p<0.001).
MOs in the eD
Of 201 patients, 58 (29%) were identified as having 
presented to the ED prior to diagnosis, 27 of whom 
(47%) had presented more than once (range 2–7 visits). 
All 58 patients had presented within 3 years preceding 
their HIV diagnosis and 53 patients (91%) within the 
preceding 12 months. Although 15 patients (26%) were 
diagnosed within 72 hours of their most recent ED visit, 7 
of these had presented to the ED on at least one previous 
occasion. In total, 50/58 patients (86%) presented to 
the ED during the interval between seroconversion and 
diagnosis, none of whom were tested. As with the patient 
sample as a whole, the two main MO categories for these 
58 patients were epidemiological risk and HIV ICs.
Table 1 Demographic characteristics of adult patients newly presenting to HIV care in Lausanne, Switzerland between 2010 
and 2015 who had not presented any missed opportunity and who had presented at least one missed opportunity
Demographic characteristic
All patients
(n=201)
Patients with 
no MO
(n=107)
Patients 
with ≥1 MO
(n=94)
Univariate 
analysis
(OR±95% CI)
Multivariate 
analysis
(adjusted 
OR±95% CI; 
p values)
Age (years), n (%)
  18–29 56 23 (41%) 33 (59%) Reference value
  30–49 112 59 (53%) 53 (47%) 0.6 (0.3 to 1.2) 0.5 (0.3 to 1.1; 0.08)
  >50 33 25 (76%) 8 (24%) 0.2 (0.1 to 0.6) 0.2 (0.1 to 0.6; <0.01)
Sex, n (%)† 
  Male 126 66 (52%) 60 (48%) Reference value
  Female 75 41 (55%) 34 (45%) 1.09 (0.6 to 1.9) 0.7 (0.3 to 1.5; 0.36)
Geographical origin, n (%)
  Europe, North America, Australasia 106 58 (55%) 48 (45%) Reference value
  Sub-Saharan Africa 66 32 (49%) 34 (51%) 1.2 (0.7 to 2.4) 3.5 (1.3 to 7.7; 0.01)
  Other‡ 29 17 (59%) 12 (41%) 0.9 (0.4 to 2.0) 1.0 (0.4 to 2.5; 0.96)
Chronic Illness, n (%)
  No 161) 92 (57%) 69 (43%) Reference value
  Yes 40 15 (37%) 25 (63%) 2.2 (1.1 to 4.5) 4.4 (1.7 to 10.9, 
<0.01)
Mode of transmission, n (%)
  Heterosexual 114 67 (59%) 47 (41%) Reference value
  MSM 68 29 (43%) 39 (57%) 1.91 (1.0 to 3.5)* 4 (1.5 to 10.7; 0.01)
  PWID 9 3 (33%) 6 (67%) 2.8 (0.7 to 12) 2.9 (0.6 to 15.3; 0.20)
  Unknown 10 8 (80%) 2 (20%) 0.3 (0.7 to 1.8) 0.3 (0.1 to 1.8; 0.2)
Time since previous HIV test, n (%)
  No previous test 119 72 (61%) 47 (39%) Reference value
  ≤1 year 28 12 (43%) 16 (57%) 2.0 (0.9 to 4.7) 1.6 (0.6 to 4.3; 0.38)
  >1 year ago 54 23 (43%) 31 (57%) 2.0 (1.0 to 4.0)* 1.4 (0.7 to 3.0; 0.31)
*P<0.05.
†There were no transgender patients in the group studied.
‡Asia, South America, North Africa, Middle East. 
MO, missed opportunity; MSM, men who have sex with men; PWID, people who inject drugs.
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DIsCussIOn
In this single-centre study, we observed that 47% of 201 
patients newly presenting for HIV care had presented 
at least one MO for earlier testing. Although 30 patients 
(15%) were diagnosed during acute infection, 9 patients 
(5%) who presented with symptoms or signs of acute HIV 
were not tested. Of patients who had visited the ED predi-
agnosis, 86% had presented at least one MO for testing. 
Finally, MOs occurred significantly less frequently in LPs 
than in non-LPs.
Our patient population differed from that of Switzer-
land as a whole (Swiss Federal Office of Public Health 
HIV notifications) in terms of HIV acquisition risk 
profile: 57% heterosexual transmission and 34% MSM, 
compared with 42% heterosexual and 57% MSM.27 As 
heterosexual transmission was a risk factor for LP in the 
Swiss HIV Cohort Study by Hachfeld et al, this might 
explain our higher rate of LPs (59%) compared with the 
Swiss HIV Cohort Study figure of 49.8%.4 A lower Swiss 
HIV Cohort Study figure through under-representation 
of our patients in the Hachfeld et al study is unlikely as 
the majority were enrolled in the Swiss HIV Cohort Study.
Our analysis showed that patients under regular 
follow-up for chronic illness, patients from sub-Saharan 
Africa and MSM were at increased risk for MOs. In patients 
under regular follow-up, there may be the assumption 
by the hospital physician that the patient’s primary care 
physician has performed an HIV test and vice versa.1 In 
our institution, we have previously reported suboptimal 
testing rates among oncology patients, particularly those 
of non-European origin.28 Among patients with risk factors 
for HIV acquisition, MOs will occur if there is non-disclo-
sure of at-risk behaviour by the patient and incomplete 
history taking by the doctor. This was described in a French 
cross-sectional study of 1008 patients newly diagnosed with 
HIV of whom 48% were MSM.29 Fewer than half the MSM 
who consulted disclosed being MSM and only 21% of all 
MSM were offered testing by their healthcare provider.29 
In Switzerland, physicians frequently do not discuss sexual 
behaviour with their patients, potentially missing such risk 
factors.30 31
Our non-association between LPs and MOs suggests a 
distinction between ‘missed’ opportunity and ‘no’ oppor-
tunity. While it is logical that LP may result from repeated 
Figure 1 Histogram showing the percentage of MOs 
occurring during the 5 years preceding diagnosis in adult 
patients newly presenting for HIV care between 2010 and 
2015 in Lausanne, Switzerland. MOs, missed opportunities.
Figure 2 Pie chart showing the distribution of the categories of missed opportunities experienced between 2010 in adult 
patients newly presenting for HIV care in Lausanne, Switzerland.  
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MOs in positive individuals, LPs do not necessarily present 
opportunities for earlier testing. If individuals feel well, 
are unaware of HIV risk factors and/or have poor access 
to healthcare, they may have sporadic if any contact with 
healthcare systems4: their LP may be their only presenta-
tion. However, this interpretation is limited by the fact that 
we were unable to quantify MOs potentially occurring in 
primary care.
We have observed in our study that LPs consult less 
frequently to our hospital. Optimal HIV testing practice is 
the cornerstone towards attaining the first 90 of the 90-90-90 
goal set by WHO.32 However, even perfect PICT practice 
cannot eliminate LP when physicians can initiate testing 
only if individuals present to them. It is necessary to reach 
out to individuals who are at risk of infection but who do 
not present for healthcare. HIV testing can be expanded by 
introducing community-level testing innovations tailored 
to each community, depending on whether non-presenta-
tion is related to lack of awareness of HIV risk factors or 
symptoms of infection or to lack of awareness of services 
available. An obstacle to HIV testing in Switzerland is that 
HIV testing may require expenditure by the patient, even if 
this is later reimbursed by health insurance. Innovations to 
improve access to testing include walk-in centres with free 
testing, testing by non-traditional providers, improving risk 
perception and tackling stigma.33
Regarding risk perception, the MO umbrella can be 
extended from MOs for HIV testing to those for HIV 
prevention. Whether or not the patients in this sample 
had HIV at their first few visits to Lausanne University 
Hospital, they were, by definition, at risk of HIV acqui-
sition. Delivering a prevention message at the time of 
testing could avert future infection and may also be a 
means of reaching individuals outside the hospital by 
dissemination of information. In the ED at our centre, 
offering non-targeted screening, as recommended in the 
USA34 and the UK,35 would have enabled diagnosis of 86% 
of the patients of our sample who had presented to this 
service. While data from our ED are lacking regarding 
the cost-effectiveness of non-targeted screening per new 
HIV diagnosis made, the prevention message that comes 
with screening could reduce onward transmission among 
contacts in the community.
The MO rates at our centre were higher than those 
reported in other studies of similarly sized samples of newly 
diagnosed patients presenting for HIV care in European 
hospital outpatient settings. Tominski et al observed a rate 
of 21% among 270 patients, based on HIV ICs12; Noble et 
al observed a rate of 16.3% among 124 patients, based on 
ICs or AIDS-defining illness up to 5 years prediagnosis14; 
Gullón et al observed a rate of 14.5% among 354 patients, 
based on ICs up to 1-year prediagnosis.15 As there is no 
consensus definition of MOs, it is important to examine the 
criteria for MOs and the time prior to diagnosis examined. 
In our study, the MO definition was wide, based on HIV 
ICs and AIDS-defining illness and on epidemiological risk, 
symptoms and signs of acute HIV infection and situations 
in which HIV should be excluded, and over a period of 
5 years prediagnosis. Considering MOs based on HIV ICs 
and AIDS-defining illness alone, our MO rate was 16%. 
However, applying the most recent HIV testing recommen-
dations, we consider the MO rate obtained according to 
our study criteria as being a baseline on which to improve. 
Considering future directions, we plan to apply the findings 
from this study in several ways. We have piloted rapid testing 
in the ED by screening patients for HIV risk factors using 
anonymous electronic tablet-based questionnaires in the 
waiting area to improve HIV testing in this service36. The 
lack of testing among pregnant women who are consulting 
to terminate their pregnancy is illogical and merits review of 
obstetrical guidelines. Finally, ICs should be mentioned in 
the practice guidelines of relevant (non-HIV) specialties.23
This study has limitations. As in any retrospective study, 
identifying and classifying MOs relied on available clin-
ical documentation. As we reviewed medical notes only 
from our institution, the number or categories of MO 
may be prone to bias. The date of the last performed HIV 
test may also be prone to recall bias. However, while the 
number of included patients was small, complete medical 
records for each patient ensured data quality. This study 
examined only MOs occurring in our hospital; using the 
Lausanne University Hospital database it was not possible 
Table 2 Clinical presentation, site of testing and reason 
for testing at time of diagnostic HIV test among all patients 
presenting to care for a newly diagnosed HIV infection 
between 2010 and 2015 in Lausanne, Switzerland
No of patients, n (%)
Clinical presentation
Acute HIV infection 30 (15)
Chronic HIV infection:
  CD4 count >350 cells/mm3 65 (32)
  Late presenters (<350 cells/mm3) 44 (22)
  Advanced disease (<200 cells/mm3) 62 (31)
Site of diagnostic HIV test
Primary care
  Primary care physician 64 (32)
  Anonymous consultation 26 (13)
Lausanne University Hospital
  Outpatient care 41 (20)
  Inpatient care 17 (8)
  Emergency department 4 (2)
  Gynaecology/obstetrics 16 (8)
  Infectious diseases service 5 (3)
  Other 28 (14)
Reason for testing
  HIV indicator condition 59 (29)
  Epidemiological risk 42 (21)
  Symptoms/signs of acute HIV infection 36 (18)
  AIDS-defining illness 21 (10)
  Pregnancy 14 (7)
  Prior to immunosuppressive treatment 1 (1)
  Patient initiated 28 (14)
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to quantify potential MOs occurring in the primary care 
setting or in other hospitals. We could therefore have 
underestimated the number of MOs. On the other hand, 
although we could determine that most diagnostic tests 
were made in the primary care setting, this study did not 
examine the untested patient denominator. As we have 
no means of quantifying HIV testing performed in the 
primary care setting, we cannot exclude an overestima-
tion of the number of MOs for our population. Finally, 
as our study was monocentric, our risk-factor associations 
with MOs reflect our local patient population. Against 
these limitations, the non-association between LP and 
MOs observed in our study has important implications for 
a national testing strategy based on PICT, as many indi-
viduals who need to be tested do not access healthcare 
before the event that leads to HIV diagnosis.
In conclusion, by defining MOs according to the most 
recent national HIV testing recommendations, we observe 
that 47% of the patients newly presenting for HIV care 
at our centre could have been tested at an earlier stage. 
The lower rate of LPs among patients presenting MOs 
suggests that the PICT approach must now be expanded 
to reach at-risk communities rather than waiting for these 
individuals to become sufficiently symptomatic to access 
care themselves.
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